Biomedical Occupation or Discipline – Page 4

FDA Approves Gilead’s Twice-Yearly HIV Prevention Shot

2 months ago talkbio0Tagged Approved, Gilead Sciences, HIV Prevention, Lenacapavir, PREP gene, public health medicine (field), twice-yearly injection, United States Food and Drug Administration, Yeztugo

FDA approval; Gilead Sciences; Lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; public health

Genentech’s Kristin Bittenbender Named BIO Board Chair Amid Industry Challenges

2 months ago talkbio0Tagged Bio, biotech industry, Biotechnology, board chair, existential threats, genentech, Kristin Bittenbender, Leadership Change, Policy, United States Food and Drug Administration

BIO; Genentech; Kristin Bittenbender; board chair; biotech industry; FDA; existential threats; leadership change; biotechnology policy

Ousted ACIP Members Criticize RFK Jr.’s ‘Destabilizing’ Changes to U.S. Vaccine Policy

2 months ago talkbio0Tagged ACIP, CDC, Centers for Disease Control and Prevention (U.S.), Committee, Decision, Employment Termination, Policy, public health medicine (field), Recommendation, RFK Jr., Vaccines

ACIP; RFK Jr.; vaccine policy; CDC; committee dismissal; public health; vaccine recommendations; destabilizing decisions

FDA Launches New Priority Review Voucher Program Aligned with National Priorities

2 months ago talkbio0Tagged Accelerated, Biopharma, CNPV, Drug Approval, national priorities, Priority Review, public health medicine (field), Review [Publication Type], United States Food and Drug Administration, unmet

FDA; priority review voucher; CNPV; biopharma; drug approval; national priorities; accelerated review; unmet public health needs

Federal Judge Rules NIH Grant Terminations Illegal, Orders Restoration of Hundreds of Grants

2 months ago talkbio0Tagged Biomedical Research, DEI, federal judge, Gender, health disparity, LGBTQ+, NIH Mouse, public health medicine (field), Racism, Sense of identity (observable entity), terminations, Trump administration

NIH; grant terminations; federal judge; racial discrimination; DEI; gender identity; Trump administration; biomedical research; public health; LGBTQ+; health disparities

Fauna Unveils ‘Fauna Brain’: An Agentic AI System Accelerating Drug Discovery with Proven Results in Lilly Collaboration

2 months ago talkbio0Tagged agentic AI, Aortic Valve Insufficiency, Brain, Comparative Genomics, Drug Discovery, Lilly collaboration, multi-agent system, Pharmaceutical Research

Fauna Brain; agentic AI; drug discovery; comparative genomics; Lilly collaboration; multi-agent system; pharmaceutical research; AI platform

BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal

2 months ago talkbio0Tagged Acquisition, all-stock, BioNTech, Biotechnology, Cancer Therapeutic Procedure, COVID-19 Vaccines, CureVac, Germany, mRNA Vaccines, Neoplasms

BioNTech; CureVac; acquisition; mRNA vaccines; cancer treatment; all-stock deal; Germany; biotechnology; oncology; COVID-19 vaccine

Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines

2 months ago talkbio0Tagged biotech partnership, cardiometabolic diseases, Collaboration, Deep Apple, G-Protein-Coupled Receptors, Nordisk, Obesity, Oral Medicine, R&D, small molecule therapeutics, Target

Novo Nordisk; Deep Apple Therapeutics; cardiometabolic diseases; oral medicines; obesity; small molecule therapeutics; GPCR target; R&D collaboration; biotech partnership

Eli Lilly Strikes $650M Deal with Juvena to Develop Muscle-Boosting Drugs

2 months ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, biotech collaboration, Drug Development, Drug Discovery, Eli, Eli Lilly, muscle health, Muscle-Boosting Drugs, Obesity, stem cell-secreted proteins

Eli Lilly; Juvena Therapeutics; muscle-boosting drugs; AI drug discovery; muscle health; biotech collaboration; stem cell secreted proteins; drug development; obesity management; $650 million deal

Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights

2 months ago talkbio0Tagged 2025, Artificial Intelligence, ASCO, Big Data, campaigns, Cancer Research, Clinical Oncology, erbB-2 Receptor, Malignant neoplasm of breast, Malignant neoplasm of lung

ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines